1792. Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation.
Ock CY, Keam BS, Kim TM, Han DH, Won TB, Lee SH, Hah JH, Kwon TK, Kim DW, Kim DY, Rhee CS, Wu HG, Sung MW, Heo DS.
Korean J Intern Med. 2016 May;31(3):570-8. doi: 10.3904/kjim.2015.020. Epub 2016 Mar 15.Link
1791. PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma.
Ock CY, Kim S, Keam BS, Kim M, Kim TM, Kim JH, Jeon YK, Lee JS, Kwon SK, Hah JH, Kwon TK, Kim DW, Wu HG, Sung MW, Heo DS.
Oncotarget. 2016 Mar 29;7(13):15901-14. doi: 10.18632/oncotarget.7431.Link
1790. Predictive and prognostic value of PET/CT imaging post-chemoradiotherapy and clinical decision-making consequences in locally advanced head & neck squamous cell carcinoma: a retrospective study.
Kim R, Ock CY, Keam BS, Kim TM, Kim JH, Paeng JC, Kwon SK, Hah JH, Kwon TK, Kim DW, Wu HG, Sung MW, Heo DS.
BMC Cancer. 2016 Feb 17;16:116. doi: 10.1186/s12885-016-2147-y.Link
1789. Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration.
Ock CY, Keam BS, Kim S, Lee JS, Kim M, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS.
Clin Cancer Res. 2016 May 1;22(9):2261-70. doi: 10.1158/1078-0432.CCR-15-2834. Epub 2016 Jan 27.Link
1788. Identification of genomic mutations associated with clinical outcomes of induction chemotherapy in patients with head and neck squamous cell carcinoma.
Ock CY, Son B, Keam BS, Lee SY, Moon J, Kwak H, Kim S, Kim TM, Jeon YK, Kwon SK, Hah JH, Lee SH, Kwon TK, Kim DW, Wu HG, Sung MW, Heo DS.
J Cancer Res Clin Oncol. 2016 Apr;142(4):873-83. doi: 10.1007/s00432-015-2083-2. Epub 2015 Dec 16.Link
1787. Effect of induction chemotherapy on survival in locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: Single center experience.
Ock CY, Keam BS, Lim Y, Kim TM, Lee SH, Kwon SK, Hah JH, Kwon TK, Kim DW, Wu HG, Sung MW, Heo DS.
Head Neck. 2016 Feb;38(2):277-84. doi: 10.1002/hed.23891. Epub 2015 Jun 18.Link
1786. Reduced Dose Intensities of Doxorubicin in Elderly Patients with DLBCL in Rituximab Era.
Ha H, Keam BS, Kim TM, Jeon YK, Lee SH, Kim DW, Kim CW, Heo DS.
Cancer Res Treat. 2016 Jan;48(1):304-11. doi: 10.4143/crt.2014.339. Epub 2015 Apr 9.Link